Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046578 | 0.74 | GRIN1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL6730153 | 0.74 | GRIN1 (0.38) | GRIN1GRIN2A | |
| SCHEMBL26829430 | 0.71 | GRIN1 (0.33) | GRIN1GRIN2A | |
| SCHEMBL7200830 | 0.71 | GRIN1 (0.33) | GRIN1GRIN2A | |
| SCHEMBL6127932 | 0.71 | — | — | |
| SCHEMBL24471011 | 0.71 | GRIN1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL26618967 | 0.71 | AR (0.36) | — | |
| SCHEMBL9800283 | 0.69 | GRIN1 (0.33) | GRIN1GRIN2A | |
| SCHEMBL15200795 | 0.67 | GRIN1 (0.34) | GRIN1GRIN2A | |
| SCHEMBL12489946 | 0.67 | GRIN1 (0.34) | GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071773-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTISAG (CH) | 2011-12-06 | — | — | US | disclosed |
| EP-1885724-B1 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-06-23 | — | — | EP | disclosed |
| US-20090111840-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2009-04-30 | — | — | US | disclosed |
| EP-1885724-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128853-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111840-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | REN, NR3C2, CYP21A2 | GRIN1 1938/4885GRIN2A 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.